Cite
HARVARD Citation
Gettinger, S. et al. (n.d.). 56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results. Lung cancer. pp. S20-S21. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gettinger, S. et al. (n.d.). 56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results. Lung cancer. pp. S20-S21. [Online].